Navigation Links
Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option
Date:12/2/2009

CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ:ONCY) announced today that in connection with its previously announced unit offering, the underwriters have exercised in full their over-allotment option and purchased an additional 637,500 units. Each unit is comprised of one common share and 0.4 of a common share purchase warrant, and was sold at a price of US$3.00 per unit. Each whole common share purchase warrant entitles the holder to acquire one common share of Oncolytics upon payment of US$3.50 for a five year period ending November 23, 2014, subject to an acceleration of the expiry date in certain circumstances. Oppenheimer & Co. Inc. acted as the sole book-running manager for the offering. Canaccord Capital Corporation and Bloom Burton & Co. acted as Canadian co-managers for the offering.

Together with the units sold on November 23, 2009, the Company has issued an aggregate of 4,887,500 units consisting of 4,887,500 common shares and 1,955,000 common share purchase warrants for total gross proceeds of US$14,662,500.

Oncolytics intends to use the net proceeds from the offering to fund its previously announced Phase III combination REOLYSIN(R) and paclitaxel/carboplatin trial for patients with platinum-failed head and neck cancers, its other clinical development and research and development activities, and for general corporate and working capital purposes.

"Completing this financing further strengthens our balance sheet and will allow us to proceed beyond the 80 patient first stage of enrollment in our Phase III clinical trial, while giving us improved flexibility in reviewing partnering options," said Dr. Brad Thompson, President and CEO of Oncolytics. "After giving effect to this financing, we have in excess of $36 million i
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 Reports ... in the United States suffer from one or more ... asthma, or cancer. Medication can address some of these ... daily activities that many sufferers face. While implanted nerve ... and stimulate the whole nerve, which can induce side ...
(Date:12/19/2014)... With only 2 weeks left of ... Sartorius Biohit products . The product specials include Buy ... Pipette Trade-in Program, and free pipette tips. , Sartorius ... the world. They are ideal for lab technicians performing ... ,     Full volume range of 0.1 uL to ...
(Date:12/19/2014)... , Dec. 18, 2014 Relmada Therapeutics, Inc. ... the treatment of chronic pain, announced the results of ... "This was a transformational year in Relmada,s history ... for our company," said Sergio Traversa , chief ... have executed on key financial, human resource and clinical ...
(Date:12/17/2014)... 2014 Achim Noack has been named ... Group. In this position, Noack will assist Jerry Stoller, ... develop marketing strategy and supervise global marketing management and ... has tremendous knowledge and experience in the crop protection ... experience and innovative thinking will be a great asset ...
Breaking Biology Technology:Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2
... LEXINGTON, Mass., Sept. 29 RainDance,Technologies announced ... a,research initiative conducted with sanofi-aventis, Paris (EURONEXT: ... of Strasbourg, France, to develop,the next generation ... The consortium was founded with the assistance ...
... Sept. 29 diaDexus, Inc.,today announced its partnership ... dedicated to combating cardiovascular disease in,current and retired ... as part,of the LHF,s cardiovascular risk assessment and ... risk for suffering a heart,attack or stroke., ...
... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... chairman and CEO,will present at the JMP Securities Healthcare ... Time at Le Parker Meridien in New York., ... discussion,of the development of picoplatin, the Company,s lead product ...
Cached Biology Technology:RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster 2RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster 3RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster 4RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster 5diaDexus, Inc. and Living Heart Foundation Offer the PLAC(R) Test to Detect Hidden Risk for Heart Attack and Stroke in Retired NFL Players 2Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference 2
(Date:12/5/2014)... 4, 2014  Tute Genomics, a leader in cloud-based ... Series A1 funding led by UK-based Eurovestech. Peak Ventures ... the investment round. "We are at a ... next-generation sequencing and seeks new approaches for the diagnosis, ... , MD MBA, and CEO of Tute Genomics. "One ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
(Date:11/21/2014)... -- According to a new market research ... Access Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), ... Geography - Global Forecasts to 2020", published by MarketsandMarkets, ... around $25 Billion in 2014 and is expected to ... of 8.69%. Browse 116 market data Tables ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... November 13, 2012Following an infection, dysregulation of the immune ... an often fatal condition called severe sepsis or septic ... underlying immune dysfunction remain poorly understood. Regulatory T cells ... to have an important role in suppressing the immune ...
... some glaciers of the Himalayas will continue shrinking for ... Young University geology professor Summer Rupper comes after her ... the monsoonal Himalayas. Published in Geophysical Research Letters ... climate remained steady, almost 10 percent of Bhutan,s glaciers ...
... PHILADELPHIA Passing one,s genes on to the next generation ... that the body would work to ensure that the genes ... New research by biologists at the University of ... the body does exactly that. This protective role is fulfilled ...
Cached Biology News:Are we closer to understanding the cause of deadly sepsis? 2Himalayan glaciers will shrink even if temperatures hold steady 2A class of RNA molecules protects germ cells from damage, Penn vet researchers show 2A class of RNA molecules protects germ cells from damage, Penn vet researchers show 3
Goat polyclonal to T7 tag (Agarose) Immunogen: Goats were immunized with MASMTGGQQMG (T7) conjugated to KLH.After multiple immunizations in Freund's adjuvant, serum was collected....
Insect Cell Lysis Buffer 50 ml...
Mouse monoclonal [11C9] to Zeralenone ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to BSA: Zeralenone...
Fas-ligand rabbit polyclonal antibody...
Biology Products: